Is AIM ImmunoTech Inc. (AIM) a Buy, Sell, or Hold?
AIM ImmunoTech Inc.
AMEX:AIM
$0.258 USD
-$0.01 (-3.01%)
- Volume
- 397.11K
- Average Volume
- 28.27M
- Market Capitalization
- $878.11K
- P/E Ratio
- -0.14
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $19.74
- Year Low
- $0.21
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.01
Industry, Sector & symbol
| Stock Exchange | AMEX |
| CEO | Thomas K. Equels |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | AIM |
| CUSIP | 00901B303 |
| CIK | 0000946644 |
| Web | https://aimimmuno.com |
| Phone | 352 448 7797 |
| Currency | USD |
| Employees | 19 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 2.15 |
| Payout Ratio | 0.00 |
| Current Ratio | 1.01 |
| Quick Ratio | 1.01 |
| Cash Ratio | 0.95 |
Sales & Book Value
| Annual Sales | $88000 |
| Price / Sales | 9.34 |
| Cash Flow | -2.68 |
| Price / Cash Flow | -0.08 |
| Price / Book | 0.53 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-8.62 |
| Trailing P/E Ratio | -0.14 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-13.96M |
| Net Margin | -14123.40% |
| Pretax Margin | -14123.40% |
| Return on Equity | 261.84% |
| Return on Assets | -154.64% |
Financials Score
| AltmanZ Score | -76.99 |
| Piotroski Score | 3.00 |
| Working Capital | 69K |
| Total Assets | 8.58M |
| Ebit | -12.28M |
| Market Cap | 905.34K |
| Total Liabilities | 6.46M |
Poll Results
About AIM ImmunoTech Inc. (AMEX:AIM) Stock
AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, and Alferon N Injection (Interferon alfa), a purified, naturally derived, multi-species alpha interferon prescribed for genital warts. Furthermore, Ampligen is currently undergoing investigation for its potential application in treating pancreatic, renal cell, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as myalgic encephalomyelitis, Hepatitis B, ... HIV, COVID-19, and post-COVID conditions. The company, originally incorporated in 1966, was formerly known as Hemispherx Biopharma, Inc. until its name change in August 2019.
CelLBxHealth builds £3.5m weighted pipeline as revenue growth target held
2026-07-15 02:58:42
CelLBxHealth PLC (AIM:CLBX, FRA:DWV), the AIM-listed cancer diagnostics company, said its commercially weighted pipeline had built to £3.5 million, supported by rising engagement from pharmaceutical and diagnostic partners. It reiterated its forecast for revenue of at least £2.1 million for the 2026 financial year, growth of at least 50% on the prior year.
2026-07-07 09:03:00
CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer
2026-07-07 09:03:00
Access it here OCALA, Fla. , July 07, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the release of its latest CEO Corner segment, featuring Chief Executive Officer Thomas Equels discussing the Company's continued momentum in pancreatic cancer and the significant clinical, strategic and operational milestones positioning Ampligen for its next stage of development.
2026-07-07 02:27:40
Coiled Therapeutics (AIM:COIL, OTCQB:COTXF), a clinical-stage oncology company developing medicines for hard-to-treat cancers, has created a new oral formulation of its lead drug candidate designed to improve how the treatment is absorbed by the body. The AIM-listed company said it expects to dose the first patient with the reformulated version of AO-252 this month.
Phoenix Copper shares drop on discount equity raise
2026-07-06 05:12:39
Phoenix Copper Ltd (AIM:PXC, OTCQX:PXCLF, FRA:5HR) said it plans to raise around £2.3 million through a placing and subscription at a steep discount, while warning that further funding will still be needed before the end of September. The AIM-listed Idaho copper developer is proposing to issue around 460 million new shares at 0.5p each, a 54.5% discount to the 1.1p closing mid-market price on 2 July.
Greatland Resources ramp-up continued through June 2026
2026-07-06 03:28:47
Greatland Resources Ltd (AIM:GGP, OTC:GRLGF, FRA:G8G, ASX:GGP) told investors that its full-year gold production topped guidance after a June quarter that also lifted its cash balance to almost US$1.3 billion with no debt. The AIM- and ASX-listed miner produced 79,099 ounces of gold and 3,573 tonnes of copper in the three months to 30 June 2026, taking full-year production to 328,986 ounces of gold and 14,594 tonnes of copper.
Update on Intention to Move from AIM to Main Market
2026-07-03 02:00:00
Reykjavík, July 03, 2026 (GLOBE NEWSWIRE) -- THIS ANNOUNCEMENT IS MADE FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE COMMON SHARES IN AMAROQ LTD. IN ANY JURISDICTION.
2026-06-24 08:29:00
OCALA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted the significant progress achieved across its pancreatic cancer development program and outlined a series of anticipated milestones that position the Company for what management believes could be a pivotal period in its evolution as a clinical-stage oncology company.
Frequently Asked Questions
-
What is the current AIM ImmunoTech Inc. (AIM) stock price?
-
AIM ImmunoTech Inc.(AMEX:AIM) stock price is $0.258 in the last trading session. During the trading session, AIM stock reached the peak price of $19.73812 while $0.21 was the lowest point it dropped to. The percentage change in AIM stock occurred in the recent session was --3.01% while the dollar amount for the price change in AIM stock was -$-0.01.
-
AIM's industry and sector of operation?
-
The AMEX listed AIM is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of AIM?
-
Robert Dickey | Chief Financial Officer
Ann Marie E. Coverly | Director of Administration & Human Resources and Deputy Investor Relations Coordinator
Peter W. Rodino | Chief Operating Officer, Executive Director of Governmental Relations, General Counsel & Secretary
Thomas K. Equels | Executive Vice Chairman, Chief Executive Officer & President
Christopher Nicodemus FACP | Member of Scientific Advisory Board & Consulting Science Officer -
How many employees does AIM have?
-
Number of AIM employees currently stands at 19. AIM operates from 2117 SW Highway 484, Ocala, FL 34473, US.
-
Link for AIM official website?
-
Official Website of AIM is: https://aimimmuno.com
-
How do I contact AIM?
-
AIM could be contacted at phone #352 448 7797 and can also be accessed through its website. AIM operates from 2117 SW Highway 484, Ocala, FL 34473, US.
-
How many shares of AIM are traded daily?
-
The average number of AIM shares traded daily for last 3 months was 28.27M.
-
What is the market cap of AIM currently?
-
The market value of AIM currently stands at $878.11K with its latest stock price at $0.258